In short
NNC0662-0419 is an investigational protein-based substance being studied for type 2 diabetes. It is given by subcutaneous injection and has no marketing authorisation. One Phase 2 trial with 290 participants is currently authorised to compare different doses of NNC0662-0419 against semaglutide (Ozempic) and placebo.
Key points
- NNC0662-0419 is an investigational protein-based substance with no marketing authorisation.
- It is being studied in a Phase 2 trial for type 2 diabetes.
- The trial plans to enrol 290 participants and is currently authorised.
- NNC0662-0419 is given by subcutaneous injection once weekly.
- The main measure is the change in HbA1c, a marker of long-term blood sugar control.
- The trial compares NNC0662-0419 with semaglutide (Ozempic) and placebo.
What is NNC0662-0419?
NNC0662-0419 is an investigational substance developed by Novo Nordisk A/S. It is a protein-based substance, meaning it is made from protein building blocks rather than being a small chemical molecule. The product records show no marketing authorisation, so it is not yet an approved medicine. The substance is classified in the therapeutic area of hormonal diseases.
How does NNC0662-0419 work?
The registry data do not describe the molecular target or mechanism of action of NNC0662-0419. The trial is designed to characterise how different doses affect HbA1c, a measure of average blood sugar over the previous two to three months. The study compares NNC0662-0419 with semaglutide (Ozempic), a medicine that belongs to the GLP-1 receptor agonist class and is used to lower blood sugar in type 2 diabetes.
Which conditions is it studied for?
- Type 2 diabetes — a long-term condition in which the body does not use insulin properly, leading to high blood sugar levels. The authorised Phase 2 trial is studying NNC0662-0419 in people with this condition.
How is NNC0662-0419 given?
NNC0662-0419 is prepared as a solution for injection and is given by subcutaneous injection, meaning it is injected under the skin. The trial summary states that NNC0662-0419 is given once weekly.
What do the clinical trials show?
One Phase 2 trial of NNC0662-0419 is registered in the EU Clinical Trials Information System. The trial is currently authorised and plans to enrol 290 participants with type 2 diabetes.
The main goal of the trial is to measure the change in HbA1c from the start of treatment, and to demonstrate and characterise the dose-response relationship of once-weekly NNC0662-0419. The study compares different doses of NNC0662-0419 with semaglutide 0.5 mg (Ozempic) and placebo.
What side effects are known?
No side effect information for NNC0662-0419 is available in the provided sources.